PARMAR KUSH sold $1.1M of TRDA (indirect holdings)
PARMAR KUSH sold 155,255 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $6.95 ($6.85–$7.00, $1.08M total) across 3 trades over 2026-08-06 to 2026-08-10.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale details (shares, price range, total value) and post-transaction holdings; it does not include any new company guidance, trial results, or deal terms.
Market read
Traders may monitor for follow-on insider activity, but this filing alone is unlikely to change valuation without additional company-specific catalysts.
What to watch
Director sales can be driven by diversification, tax planning, or pre-existing personal liquidity needs, so the signal quality is typically low without corroborating company news.
Background
The article is an SEC Form 4 insider transaction disclosure for Entrada Therapeutics, Inc. (TRDA).
Ticker impact
Entrada Therapeutics disclosed a Form 4 showing director Parmar Kush sold 155,255 shares in open-market trades for about $1.08M.
Likely limited near-term impact; any effect would be sentiment-driven and small versus fundamentals.
The filing is a primary-source Form 4, but it is an insider transaction without accompanying company news, and the disclosed sale size is modest relative to typical large-cap liquidity.
Market effects
No clear sector read-through because the disclosure is limited to an insider sale without company-specific catalysts.
None indicated.
None indicated.
Counterpoint
Absence of a stated 10b5-1 plan can be interpreted as discretionary selling, which some traders may read as caution even without fundamental changes.
Key entities
- issuerEntrada Therapeutics, Inc.
TRDA, the company whose director insider sale was reported on Form 4.
- insiderPARMAR KUSH
Director who sold 155,255 shares indirectly via open-market transactions.
